MetaCap

Fennec Pharmaceuticals (FENC) vs Valneva (VALN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fennec Pharmaceuticals (FENC) has outperformed Valneva (VALN) over the past year, gaining 66.1% versus a loss of 40.1%. Over five years, FENC leads with a +35.8% price change compared with -91.3% for VALN. Valneva is the larger company by market cap ($490.9 million vs $462.1 million), about 1.1 times the size.

On valuation, Valneva trades at a lower forward P/E (4.3x vs 12.5x for Fennec Pharmaceuticals).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FENC+66.12%VALN-40.14%
+78%+14%-50%
Nov 21, 20251 yearNov 20, 2026
FENC+33.23%VALN-89.45%
+39%-29%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FENC versus VALN key metrics
MetricFENCVALN
Share price$13.09$5.16
Market cap$462.14M$490.86M
1-day change-2.68%-3.82%
YTD return+70.00%-41.50%
1-year return+66.12%-40.14%
5-year return+35.79%-91.34%
P/E ratio (TTM)436.33—
Forward P/E12.474.34
EPS (TTM)$0.03$-2.10
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$44.64M—
Revenue growth (YoY)-6.09%—
Net income (latest FY)$-9.74M—
Operating margin-14.07%—
Net margin-21.82%—
52-week high$13.85$12.18
52-week low$5.65$4.75
Distance from 52-week high-5.49%-57.64%
Analyst consensusstrong_buynone
Avg. price target upside+34.45%+137.98%
Average volume220.87K23.10K
Shares outstanding35.31M95.13M
Employees35620
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FENC has outperformed VALN by 106.3 percentage points over the past year.

About Fennec Pharmaceuticals

FENC stock →

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees

About Valneva

VALN stock →

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees

FENC vs VALN FAQ

Which is bigger, Fennec Pharmaceuticals or Valneva?

Valneva (VALN) is larger, with a market capitalization of $490.86M compared with $462.14M for Fennec Pharmaceuticals (FENC).

Which stock has performed better over the past year, FENC or VALN?

FENC returned +66.12% over the past 12 months, compared with -40.14% for VALN (price return, excluding dividends). Past performance does not predict future results.

Are Fennec Pharmaceuticals and Valneva in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons